Rapid Micro Biosystems Q2 revenue up 10%, beats estimates

Rapid Micro Biosystems

12/08/2025 11:38

Overview

Rapid Micro Biosystems Q2 revenue grows 10%, beating analyst expectations

Net loss for Q2 was $11.9 mln, missing analyst estimates

Co enters $45 mln loan facility to strengthen financial position

Outlook

Company reaffirms full-year 2025 revenue guidance of at least $32 mln

Company expects new loan facility to support long-term growth

Rapid Micro Biosystems aims for positive cash flow in 2025

Company focuses on revenue growth and gross margin expansion

Result Drivers

SERVICE REVENUE - Service revenue grew by 18%, contributing significantly to overall revenue growth

PRODUCT REVENUE - Product revenue increased by 6%, led by mid-teens growth in consumables

GROSS MARGIN IMPROVEMENT - Gross margin improved by seven percentage points, indicating better cost management

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$7.30 mln
$7.03 mln (3 Analysts)
Q2 EPS
-$0.27
Q2 Net Income
Miss
-$11.90 mln
-$11.10 mln (3 Analysts)
Q2 Operating Expenses
$12.40 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Rapid Micro Biosystems Inc is $8.00, about 59.3% above its August 11 closing price of $3.26

Press Release: ID:nGNX80v8c6

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)